What is she best known for?
The fields of study she is best known for:
Her main research concerns Cancer research, Angiogenesis, Neovascularization, Vascular endothelial growth factor and Pathology.
Her research integrates issues of Cancer, Protein kinase B, Tyrosine kinase, Gefitinib and Lung cancer in her study of Cancer research.
As a member of one scientific family, she mostly works in the field of Angiogenesis, focusing on Cytokine and, on occasion, Proinflammatory cytokine.
Her work deals with themes such as Stromal cell, Inflammation, Endothelium, Interleukin 13 and In vivo, which intersect with Neovascularization.
Her Vascular endothelial growth factor study integrates concerns from other disciplines, such as Tumor necrosis factor alpha and Basic fibroblast growth factor.
Her Pathology research incorporates themes from Metastasis, Macrophage and Tumor growth.
Her most cited work include:
- Interleukin-17 promotes angiogenesis and tumor growth. (683 citations)
- Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. (607 citations)
- Induction of Vascular Endothelial Growth Factor by Tumor Necrosis Factor α in Human Glioma Cells POSSIBLE ROLES OF SP-1 (435 citations)
What are the main themes of her work throughout her whole career to date?
Mayumi Ono mainly investigates Cancer research, Angiogenesis, Molecular biology, Cell culture and Internal medicine.
The various areas that Mayumi Ono examines in her Cancer research study include Cancer cell, Cancer, Epidermal growth factor receptor, Gefitinib and Protein kinase B.
Her Angiogenesis research is multidisciplinary, incorporating perspectives in Endothelial stem cell, Vascular endothelial growth factor A, Vascular endothelial growth factor and Pathology.
Her Molecular biology study combines topics in areas such as Biochemistry, Mutant, Transfection, Escherichia coli and Gene.
Her research investigates the connection with Cell culture and areas like In vitro which intersect with concerns in In vivo.
Her study in Internal medicine is interdisciplinary in nature, drawing from both Endocrinology and Oncology.
She most often published in these fields:
- Cancer research (46.40%)
- Angiogenesis (28.40%)
- Molecular biology (24.40%)
What were the highlights of her more recent work (between 2009-2020)?
- Cancer research (46.40%)
- Cancer (16.40%)
- Cancer cell (14.80%)
In recent papers she was focusing on the following fields of study:
Her scientific interests lie mostly in Cancer research, Cancer, Cancer cell, Erlotinib and Epidermal growth factor receptor.
Her Cancer research research integrates issues from Protein kinase B, Gene knockdown, Internal medicine, Lung cancer and Gefitinib.
Her study in Cancer is interdisciplinary in nature, drawing from both PI3K/AKT/mTOR pathway and Pathology.
Her Cancer cell research includes elements of Angiogenesis, Cellular differentiation, Cell growth, Cell biology and Cell cycle.
Her work investigates the relationship between Angiogenesis and topics such as Vascular endothelial growth factor that intersect with problems in Tumor necrosis factor alpha.
Her Erlotinib research includes themes of Tyrosine kinase, Molecular biology and PTEN.
Between 2009 and 2020, her most popular works were:
- EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers (310 citations)
- The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial (159 citations)
- Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor–Activating Mutations (123 citations)
In her most recent research, the most cited papers focused on:
Her primary areas of investigation include Cancer research, Epidermal growth factor receptor, Lung cancer, Gefitinib and Pathology.
Her Cancer research research incorporates themes from Cell culture, Cancer cell, Signal transduction, Receptor tyrosine kinase and Erlotinib.
Her study looks at the intersection of Lung cancer and topics like Mutation with Carcinoma.
Gefitinib is a subfield of Internal medicine that Mayumi Ono explores.
Her research in Pathology intersects with topics in Cancer, Angiogenesis, Neovascularization and Tumor-associated macrophage.
Her Angiogenesis research focuses on Vascular endothelial growth factor A and how it relates to Stromal cell, Lymphangiogenesis and Interleukin.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
